Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
NCT05181618 · View on ClinicalTrials.gov ↗
Study Summary
Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.
Conditions Studied
Interventions
- DRUG Emicizumab
Study Locations (20)
Other
- Charité Universitätsklinikum Berlin — Berlin
- Universitätsklinikum Bonn — Bonn
- Észak-Pesti Centrumkórház - Honvédkórház — Budapest
- Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique — Rabat
- University Clinical Centre of Serbia — Belgrade
- Complejo Hospitalario Universitario A Coruña (CHUAC) — A Coruña
- Hospital de la Santa Creu i Sant Pau — Barcelona
- Hospital Universitario Vall de Hebron — Barcelona
- Hospital Universitario la Paz — Madrid
- Hospital Regional Universitario Carlos Haya — Málaga
São Paulo
- Hospital das Clinicas - UNICAMP — Campinas
- Hospital das Clínicas Faculdades Médicas de Ribeirão Preto — Ribeirão Preto
California
- Orthopaedic Institute for Children — Los Angeles
Florida
- University of Miami Medical Center — Miami
Oklahoma
- Oklahoma Children's Hospital ? Jimmy Everest Center — Oklahoma City
Ontario
- Hamilton Health Sciences Corporation — Hamilton
Campania
- AOU Federico II — Naples
Lazio
- Policlinico Univ. A. Gemelli — Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2027-05-21 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05181618
The ClinicalTrials.gov registry entry for NCT05181618 describes a study currently listed as active not recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Severe Hemophilia A appearing as the primary indexed condition, and to 1 intervention — of which Emicizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05181618 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, São Paulo, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05181618 about?
NCT05181618 is a clinical study titled "A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis". Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moder...
What is the current status of trial NCT05181618?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2022-06-20. Estimated completion is 2027-05-21.
What conditions does trial NCT05181618 study?
This clinical trial studies the following conditions: Severe Hemophilia A, Moderate Hemophilia A. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05181618?
The interventions under investigation include: Emicizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05181618?
This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05181618 being conducted?
This trial has 20 study locations across California, Florida, Oklahoma, São Paulo, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.